Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

The UK’s Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered into a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP discovery platform.

Under the collaboration, OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, Boehringer will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.